Golden
OncoVista Innovative Therapies

OncoVista Innovative Therapies

OncoVista Innovative Therapies is a biopharmaceutical company developing targeted anticancer therapies.

OncoVista Innovative Therapies, Inc. is a biopharmaceutical company that was incorporated on January 8, 1999. The company is engaged in developing and commercializing cancer therapies through the development of proprietary products as well as the acquisition of rights to technologies and drugs from others. OncoVista's product pipeline consists of advance (Phase 2) and early (Phase 1) clinical-stage compounds, late pre-clinical drug candidates and early pre-clinical leads.



The Company's therapeutic strategy is based on targeting the patient's tumors using tumor-associated biomarkers. Their products include: Cordycepin (OVI-123) and L-Nucleoside Conjugates (OVI-117). Cordycepin was OncoVista's first clinical-stage development compound. It depends upon the presence of a DNA polymerase, known as terminal deoxynucleotidyl transferase (TdT), for it's therapeutic activity. 



The L-nucleoside conjugate technology works by selectively targeting certain cancer cell characteristics. This makes cancer cells vulnerable to the actions of the drug, but leaves healthy cells unaffected. OVI-117 is a thymidylate synthase (TS) inhibitor with pharmacological properties, which results in a retention of efficacy and a reduction of toxicity. It has shown tumor growth inhibitory activity in human colon, breast, and prostate tumors growing in animal models.

Timeline

Funding rounds

1 Result
Funding round
Funding round
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn

Alexander Weis

CEO



Tamas Bakos

Principal Research Scientist and Project Leader



Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References